BRPI0920171A2 - processos e composições para liberação lipossômica e eficiente de terapêuticos de silenciamento de gene. - Google Patents
processos e composições para liberação lipossômica e eficiente de terapêuticos de silenciamento de gene.Info
- Publication number
- BRPI0920171A2 BRPI0920171A2 BRPI0920171A BRPI0920171A BRPI0920171A2 BR PI0920171 A2 BRPI0920171 A2 BR PI0920171A2 BR PI0920171 A BRPI0920171 A BR PI0920171A BR PI0920171 A BRPI0920171 A BR PI0920171A BR PI0920171 A2 BRPI0920171 A2 BR PI0920171A2
- Authority
- BR
- Brazil
- Prior art keywords
- liposomal
- compositions
- processes
- gene silencing
- efficient release
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1277—Processes for preparing; Proliposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Dispersion Chemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Virology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10606208P | 2008-10-16 | 2008-10-16 | |
US16737909P | 2009-04-07 | 2009-04-07 | |
PCT/US2009/060930 WO2010045512A2 (en) | 2008-10-16 | 2009-10-16 | Processes and compositions for liposomal and efficient delivery of gene silencing therapeutics |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0920171A2 true BRPI0920171A2 (pt) | 2016-07-12 |
Family
ID=41560381
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0920171A BRPI0920171A2 (pt) | 2008-10-16 | 2009-10-16 | processos e composições para liberação lipossômica e eficiente de terapêuticos de silenciamento de gene. |
Country Status (12)
Country | Link |
---|---|
US (3) | US20100112042A1 (pt) |
EP (2) | EP2349210B1 (pt) |
JP (2) | JP2012505913A (pt) |
KR (1) | KR20110071017A (pt) |
CN (2) | CN104382853A (pt) |
AU (3) | AU2009305639B2 (pt) |
BR (1) | BRPI0920171A2 (pt) |
CA (1) | CA2739046A1 (pt) |
IL (1) | IL212329A0 (pt) |
SG (1) | SG196818A1 (pt) |
WO (1) | WO2010045512A2 (pt) |
ZA (1) | ZA201102319B (pt) |
Families Citing this family (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2611944A1 (en) | 2005-06-15 | 2006-12-28 | Massachusetts Institute Of Technology | Amine-containing lipids and uses thereof |
WO2008137758A2 (en) | 2007-05-04 | 2008-11-13 | Mdrna, Inc. | Amino acid lipids and uses thereof |
EP2365962B1 (en) | 2008-11-07 | 2017-07-05 | Massachusetts Institute of Technology | Aminoalcohol lipidoids and uses thereof |
WO2010059829A2 (en) * | 2008-11-19 | 2010-05-27 | Mdrna, Inc. | Compositions and methods for triggered release rna therapeutics |
EP2496260A1 (en) | 2009-11-04 | 2012-09-12 | Marina Biotech, Inc. | Activity generating delivery molecules |
US20110244026A1 (en) | 2009-12-01 | 2011-10-06 | Braydon Charles Guild | Delivery of mrna for the augmentation of proteins and enzymes in human genetic diseases |
EP2609135A4 (en) | 2010-08-26 | 2015-05-20 | Massachusetts Inst Technology | POLY (BETA-AMINO ALCOHOLS), THEIR PREPARATION AND USES THEREOF |
CA2827118A1 (en) | 2011-02-15 | 2012-08-23 | Merrimack Pharmaceuticals, Inc. | Compositions and methods for delivering nucleic acid to a cell |
EP2691443B1 (en) | 2011-03-28 | 2021-02-17 | Massachusetts Institute of Technology | Conjugated lipomers and uses thereof |
BR112013031553A2 (pt) | 2011-06-08 | 2020-11-10 | Shire Human Genetic Therapies, Inc. | composições, mrna que codifica para uma hgla e seu uso, uso de pelo menos uma molécula de mrna e um veículo de transferência e uso de um mrna que codifica para proteína exógena |
CA2848753C (en) | 2011-09-14 | 2022-07-26 | Rana Therapeutics, Inc. | Multimeric oligonucleotide compounds |
PE20150041A1 (es) | 2011-10-27 | 2015-01-28 | Massachusetts Inst Technology | Derivados de aminoacidos funcionalizados en la terminal n capaces de formar microesferas encapsuladoras de farmaco |
TR201904389T4 (tr) | 2011-11-04 | 2019-04-22 | Nitto Denko Corp | Lipit nükleik asit partiküllerinin steril bir şekilde üretilmesine yönelik yöntem. |
EP2850190B1 (en) | 2012-05-16 | 2020-07-08 | Translate Bio MA, Inc. | Compositions and methods for modulating mecp2 expression |
AU2013262699A1 (en) | 2012-05-16 | 2015-01-22 | Rana Therapeutics, Inc. | Compositions and methods for modulating ATP2A2 expression |
US10837014B2 (en) | 2012-05-16 | 2020-11-17 | Translate Bio Ma, Inc. | Compositions and methods for modulating SMN gene family expression |
EP2850188A4 (en) | 2012-05-16 | 2016-01-20 | Rana Therapeutics Inc | COMPOSITIONS AND METHODS FOR MODULATING THE EXPRESSION OF THE MULTIGENIC FAMILY OF HEMOGLOBIN |
CA2873797A1 (en) | 2012-05-16 | 2013-11-21 | Rana Therapeutics Inc. | Compositions and methods for modulating utrn expression |
JP2015523854A (ja) | 2012-05-16 | 2015-08-20 | ラナ セラピューティクス インコーポレイテッド | Smn遺伝子ファミリー発現を調節するための組成物及び方法 |
US20150267192A1 (en) | 2012-06-08 | 2015-09-24 | Shire Human Genetic Therapies, Inc. | Nuclease resistant polynucleotides and uses thereof |
CA2884870C (en) | 2012-08-13 | 2022-03-29 | Massachusetts Institute Of Technology | Amine-containing lipidoids and uses thereof |
WO2014043544A1 (en) | 2012-09-14 | 2014-03-20 | Rana Therapeutics, Inc. | Multimeric oligonucleotide compounds |
UA117008C2 (uk) | 2013-03-14 | 2018-06-11 | Шир Хьюман Дженетік Терапіс, Інк. | IN VITRO ТРАНСКРИБОВАНА мРНК ТА КОМПОЗИЦІЯ, ЩО ЇЇ МІСТИТЬ, ДЛЯ ЗАСТОСУВАННЯ В ЛІКУВАННІ МУКОВІСЦИДОЗУ В ССАВЦЯ |
EA201591229A1 (ru) | 2013-03-14 | 2016-01-29 | Шир Хьюман Дженетик Терапис, Инк. | Способы очистки матричной рнк |
CN103172701B (zh) * | 2013-03-18 | 2015-09-30 | 中国科学院过程工程研究所 | 一种新型穿膜肽及其应用 |
PL2992874T3 (pl) | 2013-04-30 | 2019-01-31 | Delta-Fly Pharma, Inc. | Liposomy do podawania miejscowego i ich zastosowanie |
WO2014179562A1 (en) | 2013-05-01 | 2014-11-06 | Massachusetts Institute Of Technology | 1,3,5-triazinane-2,4,6-trione derivatives and uses thereof |
US10195291B2 (en) | 2013-09-24 | 2019-02-05 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for the manufacture of lipid nanoparticles |
EA201690576A1 (ru) | 2013-10-22 | 2016-10-31 | Шир Хьюман Дженетик Терапис, Инк. | Липидные композиции для доставки матричной рнк |
EP3501605B1 (en) | 2013-10-22 | 2023-06-28 | Translate Bio, Inc. | Mrna therapy for argininosuccinate synthetase deficiency |
CA2928186A1 (en) | 2013-10-22 | 2015-04-30 | Shire Human Genetic Therapies, Inc. | Mrna therapy for phenylketonuria |
KR102470198B1 (ko) | 2014-04-25 | 2022-11-22 | 샤이어 휴먼 지네틱 테라피즈 인크. | 메신저 rna 의 정제 방법 |
MA48050A (fr) | 2014-05-30 | 2020-02-12 | Translate Bio Inc | Lipides biodégradables pour l'administration d'acides nucléiques |
EP3160959B1 (en) | 2014-06-24 | 2023-08-30 | Translate Bio, Inc. | Stereochemically enriched compositions for delivery of nucleic acids |
US9840479B2 (en) | 2014-07-02 | 2017-12-12 | Massachusetts Institute Of Technology | Polyamine-fatty acid derived lipidoids and uses thereof |
CN106232124B (zh) | 2014-10-30 | 2018-01-12 | 德尔塔菲制药股份有限公司 | 制备用于局部施用的脂质体复合物的新方法及使用该脂质体复合物的抗肿瘤剂 |
JP6373749B2 (ja) | 2014-12-19 | 2018-08-15 | 富士フイルム株式会社 | リポソームの製造方法及びリポソーム製造装置 |
EP3310764B1 (en) | 2015-06-19 | 2023-04-19 | Massachusetts Institute of Technology | Alkenyl substituted 2,5-piperazinediones and their use in compositions for delivering an agent to a subject or cell |
US11564893B2 (en) * | 2015-08-17 | 2023-01-31 | Modernatx, Inc. | Methods for preparing particles and related compositions |
MA46316A (fr) | 2015-10-22 | 2021-03-24 | Modernatx Inc | Vaccin contre le cytomégalovirus humain |
US9901649B2 (en) | 2016-05-03 | 2018-02-27 | International Business Machines Corporation | Block copolymers for therapeutic drug delivery |
JP6980780B2 (ja) | 2016-10-21 | 2021-12-15 | モデルナティーエックス, インコーポレイテッド | ヒトサイトメガロウイルスワクチン |
KR101797168B1 (ko) * | 2016-11-10 | 2017-11-13 | 주식회사 바이오셀트란 | 신규의 프로테인 트랜스덕션 도메인을 함유하는 구형 구조체 |
WO2018157154A2 (en) | 2017-02-27 | 2018-08-30 | Translate Bio, Inc. | Novel codon-optimized cftr mrna |
EP3617314B1 (en) * | 2017-04-28 | 2023-02-15 | Kyowa Kirin Co., Ltd. | Oligonucleotide derivative or salt thereof |
WO2018213476A1 (en) | 2017-05-16 | 2018-11-22 | Translate Bio, Inc. | Treatment of cystic fibrosis by delivery of codon-optimized mrna encoding cftr |
EP3638215A4 (en) | 2017-06-15 | 2021-03-24 | Modernatx, Inc. | RNA FORMULATIONS |
JP7275111B2 (ja) * | 2017-08-31 | 2023-05-17 | モデルナティエックス インコーポレイテッド | 脂質ナノ粒子の生成方法 |
KR20210022535A (ko) * | 2018-04-25 | 2021-03-03 | 에트리스 게엠베하 | Rna 전달용 지질 기반 제형 |
CA3108544A1 (en) | 2018-08-24 | 2020-02-27 | Translate Bio, Inc. | Methods for purification of messenger rna |
WO2020154594A2 (en) * | 2019-01-25 | 2020-07-30 | Agenovir Corporation | Compositions and methods for treatment of human papillomavirus |
EP3915544A1 (en) * | 2020-05-25 | 2021-12-01 | Leon-Nanodrugs GmbH | Method for producing a liposome dispersion |
US11406703B2 (en) | 2020-08-25 | 2022-08-09 | Modernatx, Inc. | Human cytomegalovirus vaccine |
WO2023057596A1 (en) * | 2021-10-06 | 2023-04-13 | Leon-Nanodrugs Gmbh | Method for preparing lipid nanoparticles |
CN114569703B (zh) * | 2022-02-25 | 2023-06-13 | 纽柏抗衰老国际医生集团(广州)有限公司 | 一种助睡眠的脂质体包裹复合氨基酸的组合物及制备方法 |
CN116370437A (zh) * | 2023-05-26 | 2023-07-04 | 北京因诺惟康医药科技有限公司 | 包含胆固醇琥珀酸单酯的核酸脂质纳米颗粒组合物及其用途 |
Family Cites Families (90)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0079963B1 (en) | 1981-06-04 | 1986-08-27 | Delaware Chemicals Corporation | Pressurized container with dispensing pump |
US5208036A (en) | 1985-01-07 | 1993-05-04 | Syntex (U.S.A.) Inc. | N-(ω, (ω-1)-dialkyloxy)- and N-(ω, (ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
CH671514A5 (pt) * | 1986-12-03 | 1989-09-15 | Induchem Ag | |
US4778810A (en) | 1987-01-08 | 1988-10-18 | Nastech Pharmaceutical Co., Inc. | Nasal delivery of caffeine |
WO1989002439A1 (en) | 1987-09-21 | 1989-03-23 | Ml Technology Ventures, L.P. | Non-nucleotide linking reagents for nucleotide probes |
US5563250A (en) | 1987-12-02 | 1996-10-08 | Neorx Corporation | Cleavable conjugates for the delivery and release of agents in native form |
WO1991003162A1 (en) | 1989-08-31 | 1991-03-21 | City Of Hope | Chimeric dna-rna catalytic sequences |
US5279833A (en) | 1990-04-04 | 1994-01-18 | Yale University | Liposomal transfection of nucleic acids into animal cells |
US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
US5962219A (en) | 1990-06-11 | 1999-10-05 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: chemi-selex |
CA2093664C (en) | 1990-10-12 | 2003-07-29 | Fritz Eckstein | Modified ribozymes |
DE4216134A1 (de) | 1991-06-20 | 1992-12-24 | Europ Lab Molekularbiolog | Synthetische katalytische oligonukleotidstrukturen |
US5283185A (en) | 1991-08-28 | 1994-02-01 | University Of Tennessee Research Corporation | Method for delivering nucleic acids into cells |
US5652094A (en) | 1992-01-31 | 1997-07-29 | University Of Montreal | Nucleozymes |
US5505931A (en) | 1993-03-04 | 1996-04-09 | The Dow Chemical Company | Acid cleavable compounds, their preparation and use as bifunctional acid-labile crosslinking agents |
WO1994002595A1 (en) | 1992-07-17 | 1994-02-03 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for treatment of animal diseases |
US5334761A (en) | 1992-08-28 | 1994-08-02 | Life Technologies, Inc. | Cationic lipids |
ES2186690T3 (es) | 1993-09-02 | 2003-05-16 | Ribozyme Pharm Inc | Acido nucleico enzimatico que contiene no-nucleotidos. |
WO1995011910A1 (en) | 1993-10-27 | 1995-05-04 | Ribozyme Pharmaceuticals, Inc. | 2'-amido and 2'-peptido modified oligonucleotides |
US5627053A (en) | 1994-03-29 | 1997-05-06 | Ribozyme Pharmaceuticals, Inc. | 2'deoxy-2'-alkylnucleotide containing nucleic acid |
US6447796B1 (en) | 1994-05-16 | 2002-09-10 | The United States Of America As Represented By The Secretary Of The Army | Sustained release hydrophobic bioactive PLGA microspheres |
ATE219660T1 (de) | 1994-09-30 | 2002-07-15 | Inex Pharmaceuticals Corp | Mittel zum einbringen polyanionischer materialien in zellen |
US5753613A (en) | 1994-09-30 | 1998-05-19 | Inex Pharmaceuticals Corporation | Compositions for the introduction of polyanionic materials into cells |
US5681940A (en) | 1994-11-02 | 1997-10-28 | Icn Pharmaceuticals | Sugar modified nucleosides and oligonucleotides |
US5716824A (en) | 1995-04-20 | 1998-02-10 | Ribozyme Pharmaceuticals, Inc. | 2'-O-alkylthioalkyl and 2-C-alkylthioalkyl-containing enzymatic nucleic acids (ribozymes) |
US5705385A (en) * | 1995-06-07 | 1998-01-06 | Inex Pharmaceuticals Corporation | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
IL122290A0 (en) * | 1995-06-07 | 1998-04-05 | Inex Pharmaceuticals Corp | Lipid-nucleic acid complex its preparation and use |
US5981501A (en) * | 1995-06-07 | 1999-11-09 | Inex Pharmaceuticals Corp. | Methods for encapsulating plasmids in lipid bilayers |
US7422902B1 (en) * | 1995-06-07 | 2008-09-09 | The University Of British Columbia | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
WO1996040961A1 (en) | 1995-06-07 | 1996-12-19 | Life Technologies, Inc. | Peptide-enhanced cationic lipid transfections |
US6051429A (en) | 1995-06-07 | 2000-04-18 | Life Technologies, Inc. | Peptide-enhanced cationic lipid transfections |
US7034009B2 (en) | 1995-10-26 | 2006-04-25 | Sirna Therapeutics, Inc. | Enzymatic nucleic acid-mediated treatment of ocular diseases or conditions related to levels of vascular endothelial growth factor receptor (VEGF-R) |
US5998203A (en) | 1996-04-16 | 1999-12-07 | Ribozyme Pharmaceuticals, Inc. | Enzymatic nucleic acids containing 5'-and/or 3'-cap structures |
ATE373672T1 (de) | 1996-01-16 | 2007-10-15 | Sirna Therapeutics Inc | Synthese von methoxynukleoside und enzymatische nukleisäure moleküle |
US5849902A (en) | 1996-09-26 | 1998-12-15 | Oligos Etc. Inc. | Three component chimeric antisense oligonucleotides |
US6509320B1 (en) | 1996-10-16 | 2003-01-21 | Icn Pharmaceuticals, Inc. | Purine L-nucleosides, analogs and uses thereof |
AU738384B2 (en) | 1996-11-04 | 2001-09-20 | Qiagen Gmbh | Cationic reagents for transfection |
US6248878B1 (en) | 1996-12-24 | 2001-06-19 | Ribozyme Pharmaceuticals, Inc. | Nucleoside analogs |
US6001311A (en) | 1997-02-05 | 1999-12-14 | Protogene Laboratories, Inc. | Apparatus for diverse chemical synthesis using two-dimensional array |
US5965542A (en) * | 1997-03-18 | 1999-10-12 | Inex Pharmaceuticals Corp. | Use of temperature to control the size of cationic liposome/plasmid DNA complexes |
US6835395B1 (en) * | 1997-05-14 | 2004-12-28 | The University Of British Columbia | Composition containing small multilamellar oligodeoxynucleotide-containing lipid vesicles |
US6395713B1 (en) | 1997-07-23 | 2002-05-28 | Ribozyme Pharmaceuticals, Inc. | Compositions for the delivery of negatively charged molecules |
US6110745A (en) * | 1997-07-24 | 2000-08-29 | Inex Pharmaceuticals Corp. | Preparation of lipid-nucleic acid particles using a solvent extraction and direct hydration method |
US6734171B1 (en) * | 1997-10-10 | 2004-05-11 | Inex Pharmaceuticals Corp. | Methods for encapsulating nucleic acids in lipid bilayers |
AU1922999A (en) | 1997-12-16 | 1999-07-05 | Baylor College Of Medicine | Needle-free injection of formulated nucleic acid molecules |
US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
JP2002500201A (ja) | 1998-01-05 | 2002-01-08 | ユニバーシティ オブ ワシントン | 膜破壊剤を使用する増強された輸送 |
US6426086B1 (en) | 1998-02-03 | 2002-07-30 | The Regents Of The University Of California | pH-sensitive, serum-stable liposomes |
AU3751299A (en) | 1998-04-20 | 1999-11-08 | Ribozyme Pharmaceuticals, Inc. | Nucleic acid molecules with novel chemical compositions capable of modulating gene expression |
SK17432000A3 (sk) | 1998-05-26 | 2001-07-10 | Icn Pharmaceuticals, Inc. | Zlúčenina, ktorá zahŕňa nukleozid s 2',4'-mostíkom a oligonukleotid z nej odvodený |
JP2002537828A (ja) | 1999-03-10 | 2002-11-12 | フォゲン リミティド | 細胞への物質のデリバリー |
US6849272B1 (en) | 1999-04-21 | 2005-02-01 | Massachusetts Institute Of Technology | Endosomolytic agents and cell delivery systems |
US6083482A (en) | 1999-05-11 | 2000-07-04 | Icn Pharmaceuticals, Inc. | Conformationally locked nucleosides and oligonucleotides |
DK1102785T3 (da) | 1999-06-07 | 2013-05-13 | Arrowhead Res Corp | Sammensætninger til lægemiddeltilførsel ved anvendelse af pH-følsomme molekyler |
US7098032B2 (en) | 2001-01-02 | 2006-08-29 | Mirus Bio Corporation | Compositions and methods for drug delivery using pH sensitive molecules |
US7094423B1 (en) * | 1999-07-15 | 2006-08-22 | Inex Pharmaceuticals Corp. | Methods for preparation of lipid-encapsulated therapeutic agents |
DE60017406T2 (de) | 1999-07-15 | 2005-09-29 | Inex Pharmaceuticals Corp., Burnaby | Verfahren zur herstellung von in lipid verkapselten therapeutischen wirkstoffen |
US6200599B1 (en) | 1999-10-07 | 2001-03-13 | The Regents Of The University Of California | Ortho ester lipids |
US7833992B2 (en) | 2001-05-18 | 2010-11-16 | Merck Sharpe & Dohme | Conjugates and compositions for cellular delivery |
US20070026394A1 (en) | 2000-02-11 | 2007-02-01 | Lawrence Blatt | Modulation of gene expression associated with inflammation proliferation and neurite outgrowth using nucleic acid based technologies |
EP1203614A1 (de) * | 2000-11-03 | 2002-05-08 | Polymun Scientific Immunbiologische Forschung GmbH | Verfahren und Vorrichtung zur Herstellung von Lipidvesikeln |
US20020130430A1 (en) | 2000-12-29 | 2002-09-19 | Castor Trevor Percival | Methods for making polymer microspheres/nanospheres and encapsulating therapeutic proteins and other products |
US6897196B1 (en) | 2001-02-07 | 2005-05-24 | The Regents Of The University Of California | pH sensitive lipids based on ortho ester linkers, composition and method |
DE10109897A1 (de) | 2001-02-21 | 2002-11-07 | Novosom Ag | Fakultativ kationische Liposomen und Verwendung dieser |
US7108863B2 (en) | 2001-03-26 | 2006-09-19 | Alza Corporation | Liposome composition for improved intracellular delivery of a therapeutic agent |
WO2002087541A1 (en) * | 2001-04-30 | 2002-11-07 | Protiva Biotherapeutics Inc. | Lipid-based formulations for gene transfer |
US20030130186A1 (en) | 2001-07-20 | 2003-07-10 | Chandra Vargeese | Conjugates and compositions for cellular delivery |
US7060498B1 (en) | 2001-11-28 | 2006-06-13 | Genta Salus Llc | Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers |
US7141540B2 (en) | 2001-11-30 | 2006-11-28 | Genta Salus Llc | Cyclodextrin grafted biocompatible amphilphilic polymer and methods of preparation and use thereof |
JP2005517433A (ja) | 2002-02-20 | 2005-06-16 | サーナ・セラピューティクス・インコーポレイテッド | 短干渉核酸(siNA)を用いるTNFおよびTNFレセプタースーパーファミリー遺伝子発現のRNA干渉媒介性阻害 |
US7591994B2 (en) | 2002-12-13 | 2009-09-22 | Immunomedics, Inc. | Camptothecin-binding moiety conjugates |
EP3100719A3 (en) * | 2002-05-15 | 2017-02-22 | California Pacific Medical Center | Delivery of nucleic acid-like compounds |
JP4722481B2 (ja) * | 2002-06-28 | 2011-07-13 | プロティバ バイオセラピューティクス リミテッド | リポソーム製造方法および装置 |
CA2532228C (en) | 2003-07-16 | 2017-02-14 | Protiva Biotherapeutics, Inc. | Lipid encapsulated interfering rna |
EP1512393A1 (de) * | 2003-09-08 | 2005-03-09 | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG | Verfahren zur Herstellung von homogenen Liposomen und Lipoplexen |
CA2561221C (en) * | 2004-03-26 | 2016-09-20 | Curis, Inc. | Rna interference modulators of hedgehog signaling and uses thereof |
US7514530B2 (en) * | 2004-04-26 | 2009-04-07 | Centre National De La Recherche Scientifique | Peptide carrier for delivering siRNA into mammalian cells |
US20060040882A1 (en) * | 2004-05-04 | 2006-02-23 | Lishan Chen | Compostions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells |
JP2008500297A (ja) * | 2004-05-24 | 2008-01-10 | ポリマン サイエンティフィック イミューンバイオロジッシュ フォーシュング ゲゼルシャフト ミット ベシュレンクテル ファフツング | 薬剤送達のリポソーム |
US20070213293A1 (en) | 2005-04-08 | 2007-09-13 | Nastech Pharmaceutical Company Inc. | Rnai therapeutic for respiratory virus infection |
US20070213257A1 (en) * | 2005-08-12 | 2007-09-13 | Nastech Pharmaceutical Company Inc. | Compositions and methods for complexes of nucleic acids and peptides |
US7579318B2 (en) * | 2005-12-06 | 2009-08-25 | Centre De La Recherche De La Scientifique | Cell penetrating peptides for intracellular delivery of molecules |
EP2004141A2 (en) * | 2006-03-17 | 2008-12-24 | Novosom AG | An efficient method for loading amphoteric liposomes with nucleic acid active substances |
US20080213350A1 (en) * | 2007-02-20 | 2008-09-04 | Texas Tech University System | Encapsulation of nucleic acids in liposomes |
US20080299659A1 (en) | 2007-03-02 | 2008-12-04 | Nastech Pharmaceutical Company Inc. | Nucleic acid compounds for inhibiting apob gene expression and uses thereof |
WO2008137758A2 (en) * | 2007-05-04 | 2008-11-13 | Mdrna, Inc. | Amino acid lipids and uses thereof |
EP3045535B1 (en) | 2007-05-22 | 2018-07-25 | Arcturus Therapeutics, Inc. | Methods and uses for therapeutic oligomers |
NZ584048A (en) * | 2007-10-02 | 2012-08-31 | Marina Biotech Inc | Lipopeptides for delivery of nucleic acids |
US11625808B2 (en) | 2020-07-30 | 2023-04-11 | Arm Limited | Graphics processing systems |
-
2009
- 2009-10-16 US US12/580,250 patent/US20100112042A1/en not_active Abandoned
- 2009-10-16 KR KR1020117011136A patent/KR20110071017A/ko not_active Application Discontinuation
- 2009-10-16 CA CA2739046A patent/CA2739046A1/en not_active Abandoned
- 2009-10-16 BR BRPI0920171A patent/BRPI0920171A2/pt not_active Application Discontinuation
- 2009-10-16 EP EP09744527.4A patent/EP2349210B1/en not_active Not-in-force
- 2009-10-16 SG SG2014002885A patent/SG196818A1/en unknown
- 2009-10-16 JP JP2011532268A patent/JP2012505913A/ja active Pending
- 2009-10-16 WO PCT/US2009/060930 patent/WO2010045512A2/en active Application Filing
- 2009-10-16 CN CN201410524574.9A patent/CN104382853A/zh active Pending
- 2009-10-16 EP EP15153333.8A patent/EP2902013A1/en not_active Withdrawn
- 2009-10-16 CN CN200980148321.3A patent/CN102231979B/zh not_active Expired - Fee Related
- 2009-10-16 AU AU2009305639A patent/AU2009305639B2/en not_active Ceased
-
2011
- 2011-03-29 ZA ZA2011/02319A patent/ZA201102319B/en unknown
- 2011-04-14 IL IL212329A patent/IL212329A0/en unknown
-
2012
- 2012-06-20 US US13/527,723 patent/US20130039970A1/en not_active Abandoned
-
2014
- 2014-12-11 JP JP2014251287A patent/JP6126072B2/ja active Active
-
2015
- 2015-04-09 US US14/682,314 patent/US20150209283A1/en not_active Abandoned
-
2016
- 2016-08-31 AU AU2016222371A patent/AU2016222371A1/en not_active Abandoned
-
2018
- 2018-06-25 AU AU2018204605A patent/AU2018204605A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP2012505913A (ja) | 2012-03-08 |
WO2010045512A3 (en) | 2011-01-27 |
EP2902013A1 (en) | 2015-08-05 |
KR20110071017A (ko) | 2011-06-27 |
CN104382853A (zh) | 2015-03-04 |
US20100112042A1 (en) | 2010-05-06 |
CA2739046A1 (en) | 2010-04-22 |
AU2018204605A1 (en) | 2018-07-12 |
AU2009305639B2 (en) | 2016-06-23 |
SG196818A1 (en) | 2014-02-13 |
JP6126072B2 (ja) | 2017-05-10 |
US20150209283A1 (en) | 2015-07-30 |
EP2349210B1 (en) | 2015-03-18 |
IL212329A0 (en) | 2011-06-30 |
WO2010045512A2 (en) | 2010-04-22 |
AU2009305639A1 (en) | 2010-04-22 |
AU2016222371A1 (en) | 2016-09-15 |
CN102231979A (zh) | 2011-11-02 |
EP2349210A2 (en) | 2011-08-03 |
JP2015096529A (ja) | 2015-05-21 |
US20130039970A1 (en) | 2013-02-14 |
CN102231979B (zh) | 2014-10-29 |
ZA201102319B (en) | 2012-09-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0920171A2 (pt) | processos e composições para liberação lipossômica e eficiente de terapêuticos de silenciamento de gene. | |
BRPI1010885A2 (pt) | motivos de modificação química para inibidores mirna e miméticos. | |
BRPI0907008A2 (pt) | Métodos otimizados para liberação de dsrna alvejando o gene pcsk9 | |
BRPI0909780A2 (pt) | Composições e métodos para liberação de fármaco | |
BRPI0910608A2 (pt) | métodos e sistemas para avaliar resultados clínicos | |
BRPI0908042A2 (pt) | válvula de ação contra-rebite para sistema de exaustão | |
BRPI0908379A2 (pt) | sistemas e métodos para obter dentaduras customizadas | |
BRPI0915492A2 (pt) | sistemas e métodos para transferir valores | |
BRPI0913924A2 (pt) | métodos e sistemas para avaliação de infertilidade clínica | |
BRPI0920072A2 (pt) | métodos para separação e caracterização de micro-organismos por agentes identificadores | |
BRPI0908079A2 (pt) | Conjunto motor para aeronave, e, aeronave | |
BRPI0920980A2 (pt) | saída para gás. | |
BRPI0907771A2 (pt) | Conjunto motor para aeronave, e, aeronave | |
BRPI0905954A2 (pt) | Âncora para manipulação de elementos de construção compreendendo ramos divergentes | |
GB0816778D0 (en) | Gene silencing | |
BRPI1010859A2 (pt) | aptâmero para quimase, e uso do mesmo | |
BRPI0910286A2 (pt) | métodos para transformação de levedura | |
BR112012004699A2 (pt) | Métodos e composições para lise química direta | |
BRPI0921087A2 (pt) | válvula para utilização universal e diversas finalidades | |
BRPI0907959A2 (pt) | Conjunto motor para aeronave, e, aeronave | |
BRPI0718035A2 (pt) | Método e disposição para fabricação de metanol | |
BRPI0813388A2 (pt) | Métodos e composições para amplificação de ácido nucleico | |
BRPI0918232A2 (pt) | Enzimas e métodos para degradação de s-triazinas e diazininas | |
EP2142672A4 (en) | COMPOSITIONS AND METHODS FOR SILENCING GENES | |
BRPI0922729A2 (pt) | métodos e sistemas para remoção de hidrocarbonetos pesados. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |